10b. The Rationale for Aggressive Therapy for Diabetic Dyslipidemia

Sunday, September 17, 2000
14:30 - 16:30

14:00-14:30 Refreshments (Ballroom C)
14:30-14:35 Introduction
M-R Taskinen, Finland
14:35-14:40 Presentation of case study
M-R Taskinen, Finland
14:40-14:50 Audience interactive session related to the case study
M-R Taskinen, Finland
14:50-15:10 Lipid abnormalities in patients with type 2 diabetes and cardiovascular disease
M. Laakso, Finland
15:10-15:15 Q and A session
15:15-15:35 The multiple risk factor patient
R. R. Henry, USA
15:35-15:40 Q and A session
15:40-16:00 Defining aggressive goals for treating dyslipidemia in diabetes
S. Haffner, USA
16:00-16:05 Q and A session
16:05-16:25 Recap of case study, with second audience interactive session and panel discussion - All
16:25-16:30 Summary and conclusions
M-R Taskinen, Finland
16:30 Close

 
Renaissance Hotel


Marja-Riitta Taskinen, Finland

Pfizer Inc.
Parke Davis

FOR GENERAL ENQUIRIES
Charlie Bellinger, PPSI
Wicker House, High Street
Worthing, West Sussex, BN11 1DJ, UK
Tel: +44 1903 288203
Fax: + 44 1903 282707
E-mail: cbellinger@hbase.com

FOR REGISTRATION ENQUIRIES
Helen Capelin, PPSI
3 Liverpool Gardens, Worthing
West Sussex, BN11 1TF, UK
Tel: +44 1903 703044
Fax: +44 1903 703001
E-mail: hcapelin@hbase.com

FOR ABSTRACT ENQUIRIES
Charlie Bellinger, PPSI,
Wicker House, High Street, Worthing,
West Sussex, BN11 1DJ, UK
Tel: +44 1903 288203
Fax: + 44 1903 282707
E-mail: cbellinger@hbase.com